Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic ...
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to one year Dupixent is the first-ever medicine in the EU …